Related Experiment Video
Updated: Dec 5, 2025
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Renoprotective Effect of Formononetin by Suppressing Smad3 Expression in Db/Db Mice
Jiawei Lv1, Kai Zhuang1, Xiyu Jiang1
1Department of Pharmacology, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 510006, People's Republic of China.
Purpose:
Glomerular sclerosis and renal interstitial fibrosis are the most important pathologies in the development of kidney damage under diabetic conditions. Smad3 plays antagonistic roles in high glucose-induced renal tubular fibrosis, which is an important treatment target for diabetic nephropathy (DN). Formononetin (FMN) has multiple effects on diabetic vascular complications including DN. However, whether it plays an anti-fibrosis role by regulating smad3 is unclear. The purpose of this study was to evaluate the renoprotective effect of FMN by suppressing smad3 expression in db/db mice.
Methods:
FMN was orally administered to db/db mice with a dose of 25 or 50 mg/kg/day for 8 weeks. At the end of the study, serum, urine, and kidney samples were collected for biochemical and pathological examinations. The expressions of proteins and mRNA associated with renal fibrosis were determined by biochemical, histological, immunofluorescence, and real-time PCR analysis.
Results:
The results showed that FMN substantially improved the glucolipid metabolism, reduced the oxidative stress, and protected renal function in db/db mice. Meanwhile, protein and mRNA expression of smad3 and related regulatory factor of extracellular matrix deposition were significantly suppressed.
Conclusion:
The present study suggested that FMN has a good renoprotective effect in DN, which plays an anti-fibrosis role in db/db mice by suppressing the expression of smad3.
Insights
Formononetin (FMN) demonstrates renoprotective effects in diabetic nephropathy (DN) by improving metabolic health and reducing oxidative stress. This study shows FMN suppresses smad3 expression, offering a potential therapeutic strategy for kidney damage in diabetes.
Area of Science:
- Nephrology
- Endocrinology
- Pharmacology
Background:
- Diabetic nephropathy (DN) is characterized by glomerular sclerosis and renal interstitial fibrosis.
- Smad3 signaling is implicated in high glucose-induced renal tubular fibrosis, a key target for DN treatment.
- Formononetin (FMN) is known to affect diabetic vascular complications, but its role in DN via smad3 is not fully understood.
Purpose of the Study:
- To investigate the renoprotective effects of Formononetin (FMN) in a mouse model of diabetic nephropathy (DN).
- To determine if FMN exerts its protective effects by suppressing smad3 expression.
Main Methods:
- Formononetin (FMN) was administered orally to db/db mice at doses of 25 or 50 mg/kg/day for 8 weeks.
- Serum, urine, and kidney tissues were analyzed for biochemical and pathological changes.
- Expression of proteins and mRNA related to renal fibrosis and extracellular matrix deposition was assessed using various techniques including real-time PCR.
Main Results:
- FMN treatment significantly improved glucolipid metabolism and reduced oxidative stress in db/db mice.
- Renal function was protected in FMN-treated mice.
- Protein and mRNA expression of smad3 and extracellular matrix deposition factors were significantly suppressed by FMN.
Conclusions:
- Formononetin (FMN) exhibits significant renoprotective effects in diabetic nephropathy (DN).
- FMN acts as an anti-fibrotic agent in db/db mice by downregulating smad3 expression.
- These findings suggest FMN as a potential therapeutic agent for managing DN.
More Related Videos
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
07:38Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018